Human uterus adenocarcinoma. Established from a 63 year old female with adenocarcinoma of the uterus. COLO 684 was established from the same patient as confirmed by STR profiling.
D-685, a prodrug of D-520, exhibits higher in vivo anti-Parkinsonian efficacy in a reserpinized Parkinson's disease (PD) animal model than the parent D-520. D-685 reduces accumulation of human α-synuclein (α-syn) protein. D-685 exhibits facile brain penetration[1].